60 Degrees Pharmaceuticals enrolls first patient in expanded access study of tafenoquine for persistent babesiosis

60 DEGREES PHARMACEUTICALS, INC.

First patient enrolled in NCT06478641, an expanded access study of tafenoquine for persistent babesiosis after standard-of-care failure.
Prior case series in Clinical Infectious Diseases reported 80% cure rate with tafenoquine plus SOC in five high-risk patients.
Company estimates cumulative U.S. accessible market for ARAKODA (tafenoquine) in babesiosis may exceed 400,000 patients through Dec 2035.
Tafenoquine is FDA-approved for malaria prophylaxis (ARAKODA) but not proven effective or approved for babesiosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.